Results from animal experiments indicate that intranasal administration of hyperoside (at doses of 20, 40, and 80 mg/kg, administered once every 3 days for 8 weeks) significantly improved cognitive function and motor coordination in APP/PS1 double-transgenic Alzheimer’s disease mice. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.